There is a lot of support in the 1.70's. With such low volume just a few dedicated buyers can keep it right there. I'm one of them, although I've already bought a fair number of shares. At 1.60 I would dig into the safe a little deeper!
Single-dose non-inferiority with Daptomycin in the trial that just started and we are looking at 5 bucks or so. We certainly should have that answer within 12 months. Even without that result, we should have Phase 1 data on Kevetrin by that time as well. Who knows what that would do to the price? With those catalysts on the horizon, any sellers must have a VERY short term trading horizon.
Over the next 12 months, I will trade out a small portion of my shares for repurchase only if the stock is clearly overheated. There is some chance of an NNVC style bashing party, and if that happens I will approach it as a buying opportunity.
Market Data 
Markets 
AI
